Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
20.10.2026 15:02:00 CEST | Business Wire | Press Release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community.
“At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinical relevance of our data, and delivering value to patients, healthcare professionals, and biopharma partners,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “We look forward to presenting new findings and connecting with the oncology community to discuss how Guardant’s solutions can advance cancer care globally.”
Key data that will be presented include:
-
Rapid Oral 283RO: Assessing bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer by fibroblast growth factor receptor 2 (FGFR2) amplification status in the FORTITUDE study, which suggests that FGFR2 amplification may identify a more treatment-sensitive subgroup.
Friday, Oct. 23, 2026, Session: 4:15-5:45 p.m., Presentation: 5:19-5:24 p.m., Location: Almeria Auditorium - Hall 9
-
Rapid Oral LBA73: Evaluating ctDNA-guided treatment intensification in untreated advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) to identify patients who may benefit from intensified first-line therapy in the PACE-LUNG study—a multicenter, Phase II trial of additional chemotherapy for patients with persistent EGFR-mutant ctDNA in plasma at Week 3 after starting first-line osimertinib.
Saturday, October 24, 2026, Session: 8:30-10 a.m., Presentation: 8:30-8:35 a.m., Location: Almeria Auditorium - Hall 9
-
Rapid Oral 2636RO: Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib from the CROWN study. Findings suggest that baseline genomic complexity and on-treatment changes in methylation-based tissue-free assays may help identify patients at risk of early progression.
Saturday, Oct. 24, 2026, Session: 8:30-10 a.m., Presentation: 9:05-9:10 a.m., Location: Almeria Auditorium - Hall 9
-
Poster 4403P: Using serial Guardant360® Liquid testing in a Phase 2 study with MD Anderson to examine clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer to distinguish genuine resistance evolution from changes caused by fluctuating ctDNA levels, potentially improving patient selection for anti-EGFR rechallenge.
Friday, October 23, 2026, Session: 3:15-4 p.m.
-
Poster 2566P: Exploring post-surgical MRD and pathological complete response (pCR) after perioperative nivolumab in resectable Stage III NSCLC. In this exploratory analysis from NADIM II, pCR was associated with MRD negativity and excellent 5-year survival. In non-pCR patients, MRD negativity identified patients with favorable long-term outcomes, whereas detectable MRD defined a high-risk subgroup with early recurrence.
Monday, October 26, 2026, Session: 12-12:45 p.m.
Additional Guardant Health presentations at ESMO 2026
Abstract | Full abstract title | Session details |
Poster
| Impact of blood draw weekday on turnaround time of Guardant360® CDx liquid biopsy: A real-world analysis |
Basic science
|
Poster
| Longitudinal ctDNA monitoring and radiological response to targeted therapies in early-phase clinical trials |
Developmental therapeutics
|
Poster
| Clinical utility and interpretation challenges of circulating comprehensive genomic profiling in routine oncology practice |
Pathology and molecular pathology
|
Poster
| Trastuzumab deruxtecan vs physician’s choice of chemotherapy in HR+, HER2-low metastatic breast cancer: A DESTINY-Breast06 ctDNA molecular response analysis |
Translational research and biomarkers
|
Poster
| Genomic landscape of cancer of unknown primary: Prognostic stratification through molecular profiling |
Translational research and biomarkers
|
Poster
| Beyond HER2 IHC: ERBB2 RNA-ISH stratifies benefit from T-DXd combinations |
Translational research and biomarkers
|
Poster
| Clinical efficacy and predictive biomarkers of mTOR inhibition combined with endocrine therapy following progression on PI3K inhibitors in hormone receptor–positive metastatic breast cancer |
Advanced breast cancer, other
|
Poster
| Real-world elacestrant outcomes in ESR1-mutant HR+/HER2− metastatic breast cancer: A two-center NHS audit |
Advanced breast cancer, other
|
Poster
| Clinical and molecular characteristics of leptomeningeal disease in metastatic breast cancer patients: A prospective observational registry study |
CNS tumors
|
Rapid oral
| ctDNA-guided re-treatment with encorafenib and cetuximab in patients with chemorefractory BRAFV600E mutated metastatic colorectal cancer (mCRC): The proof-of-concept single arm phase II BRICKET trial by GONO |
Rapid oral: Gastrointestinal tumors, lower digestive
|
Poster
| Baseline ctDNA and the efficacy of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant mCRC from BAYONET trial |
Colon cancer
|
Rapid oral
| Molecular response in KIT circulating ctDNA from StrateGIST 1: A phase 1/1b study of velzatinib (IDRX-42) in patients with advanced gastrointestinal stromal tumors |
Rapid oral: Sarcoma
|
LBA - 4037 | ctDNA negative hyperselection as an effect modifier of treatment sequence efficacy in left-sided RAS wild-type mCRC: pre-specified exploratory analysis of the CR-SEQUENCE | TBD |
LBA 2882eP | ctDNA assessment in patients with CLDN18.2+, HER2−, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in SPOTLIGHT | TBD |
ePoster-2813eP | A decade of ctDNA-NGS in NSCLC: Real-world evolution of actionability and liquid-first clinical use | ePoster: NSCLC, metastatic |
ePoster- | Combined cfDNA and ctDNA analysis improves prognostic models in patients referred for early-phase clinical trials | ePoster: Translational research and biomarkers |
ePoster- 2734eP | Clinical significance of comprehensive genomic profiling after negative initial CDx testing in advanced NSCLC | ePoster: NSCLC, metastatic |
ePoster TiP-3584eTiP | Consolidation XELOX plus dostarlimab after chemoradiation with optional adjuvant dostarlimab in pMMR/MSS or MSI-low locally advanced rectal cancer: The IMMUNOSTAR phase II randomized trial (GOIRC-02-2024) | ePoster Trial in progress: Rectal and anal cancer |
ePoster-2783eP | Sequential liquid biopsy in advanced NSCLC | ePoster: NSCLC, metastatic |
ePoster-4185eP | The value of liquid biopsy in pleural mesothelioma as a biomarker strategy in clinical trials selection | ePoster: Thoracic malignancies, other |
The full abstracts for Guardant Health at ESMO 2026 can be found on the ESMO website.
Since 2020, Guardant has established public-private partnerships (PPPs) with leading healthcare institutions and cancer centers in Europe including The Royal Marsden NHS Foundation Trust (UK), Vall d’Hebron Institute of Oncology (Spain), and Policlinico Gemelli (Italy) to localize advanced diagnostic testing, generate clinical/economic evidence, and ultimately expand reimbursement and adoption. These partnerships make it possible to deliver high quality, clinical grade testing, similar to tests administered in the U.S., with local validation supporting research, delivering faster diagnoses, and increasing access to targeted treatments.
To learn more about the PPPs and Guardant Health during ESMO, visit the team at Booth #8058.
About Guardant360® Liquid
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal®
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsyshowed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
About Guardant360® CDx
Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer, and colorectal cancer.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261019515698/en/
Contacts
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Meaghan Smith
press@guardanthealth.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform20.10.2026 17:00:00 CEST | Press Release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced today the introduction of its Cessna Grand Caravan EX Veris Virtual Reality Flight Training Device (FTD), expanding the Veris product line to support one of the aviation industry's most versatile and widely utilized aircraft platforms. The announcement marks the first Caravan-configured training device offered within TRU Simulation's portfolio and reflects the company's continued investment in immersive aviation training technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020834162/en/ TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform "The Veris platform was created to make high-fidelity simulation accessible to more operators and training organizations, helping to meet the growing need for efficient pilot training and proficiency development ac
92% of Compliance Leaders Want External Certification on AI Agents. None Exists for On-Chain Risk. Elliptic Just Built It, for Free.20.10.2026 16:00:00 CEST | Press Release
Elliptic, the leader in on-chain risk management, today launched the first certification in governing AI agents for on-chain risk and financial crime compliance from the Elliptic Institute. The Certified Agentic On-Chain Risk Practitioner (CAORP) Foundation Level is free and open to anyone in the industry. The certification follows new Elliptic research in which 92% of senior risk, compliance and financial crime professionals said they would consider sending staff for external certification in agentic AI risk governance. The global research1 found a wide gap between that appetite and teams' current capability. Only 16% of respondents said they were very confident their team has the skills to govern an AI agent today, while 38% said they were not confident at all or had no capability yet. Nearly a third (31%) expect to send staff for certification within the next 12 months. The demand for training has arrived well ahead of anywhere to get it. The timing isn't optional. The EU AI Act now
Xceedance Named a Leader and Star Performer in Everest Group’s Insurance Intermediaries Operations PEAK Matrix ® Assessment 202620.10.2026 16:00:00 CEST | Press Release
Xceedance today announced it has been named a Leader and Star Performer in the Everest Group Insurance Intermediaries Operations PEAK Matrix® Assessment 2026. The assessment evaluated 18 providers based on market impact and their vision and capability to deliver insurance intermediary operations services. Everest Group identified Xceedance’s support for MGAs and MGUs across entity setup and licensing, underwriting, policy administration, finance, analytics, and claims as a key strength. The report also highlighted enabling rapid program launches and scaling through a licensed MGA shell, configurable workflows, and integrated operations. “Xceedance brings deep insurance expertise and a growing breadth of capabilities to support MGAs, brokers, and Lloyd’s market participants,” said Dinesh Udawat, Practice Director, Everest Group. “Its strategic acquisitions have expanded its agent and broker capabilities, while continued investments in AI and insurance-specific technology are enabling mo
Andersen Consulting Adds Collaborating Firm in Uzbekistan20.10.2026 15:30:00 CEST | Press Release
Andersen Consulting expands its cybersecurity and business transformation capabilities through a Collaboration Agreement with Algoruni, a consulting firm based in Uzbekistan. Algoruni advises organizations on building cyber resilience, while addressing broader management, regulatory, and sustainability priorities. Operating out of Tashkent, the firm’s services span cybersecurity strategy and data protection, corporate governance and operational improvement, and ESG strategy and reporting, with an emphasis on practical solutions tailored to each client’s circumstances. “Every organization faces a different combination of risks and opportunities, which is why we believe effective solutions must start with the realities of the business,” said Alisher Zaynutdinov, managing director of Algoruni. “Becoming a collaborating firm of Andersen Consulting allows us to pair this approach with broader international resources and perspectives, giving us new ways to help clients turn complex challenge
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 15:30:00 CEST | Press Release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom